TABLE 1.

Overview of the analytic study population

Trial	Histology	Therapy tested	Cumulative prescribed doxorubicin dose, mg/m2	DRZ statusa	Cumulative prescribed etoposide dose, mg/m2	No. eligible enrolled overall	No. US residentsb	No. Treated at PHIS sitec
DFCI 95–01 high risk arm	Pre-B/T-cell ALL	DFCI 87–01 treatment backbone, addition of high-dose methotrexate, E. Coli vs Erwinia Asparaginase; cranial RT 18 Gy	300	1:1 random-ization	0	58d	58	58
P9404	T-cell ALL	DFCI 87–01 treatment backbone, ±high-dose methotrexate; cranial RT 18 Gy	360	1:1 random-ization	0	537	489	163
P9425	Intermediate/advanced risk Hodgkin lymphoma	Response-adapted, 3–5 cycles DBVE +PC; involved region RT 21 Gy	180–300	1:1 random-ization	1125–1875	216	183	51
P9426	Low risk Hodgkin lymphoma	Response-adapted, 2–4 cycles DBVE; involved field RT 25.5 Gy	100–200	1:1 random-ization	1000–2000	255	230	79
P9754	Localized osteosarcoma	MAP or MAP/ifosfamide, with either doxorubicin or ifosfamide/etoposide intensification if standard response	450–600	All received DRZ	0 –1500	242e	217	90
CCSS	Osteosarcomaf	N/A	40–1170g	No DRZ	N/A	495	495	N/A

ALL, acute lymphoblastic leukemia/lymphoma; CCSS, Childhood Cancer Survivor Study; DBVE, doxorubicin, bleomycin, vincristine, etoposide; DFCI, Dana-Farber Cancer Institute; DRZ, dexrazoxane; Gy, Gray; MAP, methotrexate, doxorubicin, cisplatin; N/A, not applicable; PC, prednisone, cyclophosphamide; PHIS, Pediatric Health Information System; RT, radiotherapy

^aIn all trials, DRZ was given as an intravenous bolus before each doxorubicin dose in a DRZ:doxorubicin dose ratio of 10:1

^bOnly these individuals were linked with the National Death Index (through December 2017), Organ Procurement and Transplantation Network (through March 2019), and Medicaid claims (through December 2010)

^cData available through December 2018

^dDue to regulatory reasons, only patients directly enrolled at DFCI (and not at consortium sites) were available for this analysis; the overall trial enrolled 219 patients on the high-risk arm

^eIf limited to 5-year survivors, n=144

^fInitial disease stage information not collected, but cohort is limited to ≥5-year survivors by design

^gCCSS doses are received doses, with median 379 mg/m² (interquartile range 288–455)